Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generate transformative medicines for cancer and autoimmune disorders. Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious. Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/17/20 | $82,000,000 | Series A |
Canaan Partners Samsara BioCapital The Column Group | undisclosed |
| 01/06/23 | $100,000,000 | Series C |
The Column Group | undisclosed |
